Literature DB >> 19141711

Functional genetic variation in the basal promoter of the organic cation/carnitine transporters OCTN1 (SLC22A4) and OCTN2 (SLC22A5).

Harunobu Tahara1, Sook Wah Yee, Thomas J Urban, Stephanie Hesselson, Richard A Castro, Michiko Kawamoto, Doug Stryke, Susan J Johns, Thomas E Ferrin, Pui-Yan Kwok, Kathleen M Giacomini.   

Abstract

The organic cation/ergothioneine transporter OCTN1 (SLC22A4) and the high-affinity carnitine transporter OCTN2 (SLC22A5), play an important role in the disposition of xenobiotics and endogenous compounds. Here, we analyzed the sequence of the proximal promoter regions of OCTN1 and OCTN2 in four ethnic groups and determined the effects of the identified genetic variants on transcriptional activities and mRNA expression. Six variants were found in the proximal promoter of OCTN1, one of which showed high allele frequency ranging from 13 to 34% in samples from individuals with ancestries in Africa, Europe, China, and Mexico. OCTN1 haplotypes had similar activities as the reference in luciferase reporter assays. For OCTN2, three of the seven variants identified in the proximal promoter showed allele frequencies greater than 29.5% in all populations, with the exception of -207C>G (rs2631367) that was monomorphic in Asian Americans. OCTN2 haplotypes containing -207G, present in all populations, were associated with a gain of function in luciferase reporter assays. Consistent with reporter assays, OCTN2 mRNA expression levels in lymphoblastoid cell lines (LCLs) from gene expression analysis were greater in samples carrying a marker for -207G. This SNP seems to contribute to racial differences in OCTN2 mRNA expression levels in LCLs. Our study with healthy subjects (n = 16) homozygous for either -207C or -207G, showed no appreciable effect of this SNP on carnitine disposition. However, there were significant effects of gender on carnitine plasma levels (p < 0.01). Further in vivo studies of OCTN2 promoter variants on carnitine disposition and variation in drug response are warranted.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19141711      PMCID: PMC2670604          DOI: 10.1124/jpet.108.146449

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  33 in total

1.  beta-lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter.

Authors:  M E Ganapathy; W Huang; D P Rajan; A L Carter; M Sugawara; K Iseki; F H Leibach; V Ganapathy
Journal:  J Biol Chem       Date:  2000-01-21       Impact factor: 5.157

2.  Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition.

Authors:  K Bleasby; J C Castle; C J Roberts; C Cheng; W J Bailey; J F Sina; A V Kulkarni; M J Hafey; R Evers; J M Johnson; R G Ulrich; J G Slatter
Journal:  Xenobiotica       Date:  2006 Oct-Nov       Impact factor: 1.908

Review 3.  Genetic polymorphisms of drug transporters: pharmacokinetic and pharmacodynamic consequences in pharmacotherapy.

Authors:  Ichiro Ieiri; Hiroshi Takane; Takeshi Hirota; Kenji Otsubo; Shun Higuchi
Journal:  Expert Opin Drug Metab Toxicol       Date:  2006-10       Impact factor: 4.481

Review 4.  The pharmacogenetics research network: from SNP discovery to clinical drug response.

Authors:  K M Giacomini; C M Brett; R B Altman; N L Benowitz; M E Dolan; D A Flockhart; J A Johnson; D F Hayes; T Klein; R M Krauss; D L Kroetz; H L McLeod; A T Nguyen; M J Ratain; M V Relling; V Reus; D M Roden; C A Schaefer; A R Shuldiner; T Skaar; K Tantisira; R F Tyndale; L Wang; R M Weinshilboum; S T Weiss; I Zineh
Journal:  Clin Pharmacol Ther       Date:  2007-03       Impact factor: 6.875

5.  Regional distribution of solute carrier mRNA expression along the human intestinal tract.

Authors:  Yvonne Meier; Jyrki J Eloranta; Jutta Darimont; Manfred G Ismair; Christian Hiller; Michael Fried; Gerd A Kullak-Ublick; Stephan R Vavricka
Journal:  Drug Metab Dispos       Date:  2007-01-12       Impact factor: 3.922

6.  Refined genomic localization and ethnic differences observed for the IBD5 association with Crohn's disease.

Authors:  Mark S Silverberg; Richard H Duerr; Steven R Brant; Gillian Bromfield; Lisa W Datta; Niraj Jani; Sunanda V Kane; Jerome I Rotter; L Philip Schumm; A Hillary Steinhart; Kent D Taylor; Huiying Yang; Judy H Cho; John D Rioux; Mark J Daly
Journal:  Eur J Hum Genet       Date:  2007-01-10       Impact factor: 4.246

7.  Functional genetic diversity in the high-affinity carnitine transporter OCTN2 (SLC22A5).

Authors:  Thomas J Urban; Renata C Gallagher; Chaline Brown; Richard A Castro; Leah L Lagpacan; Claire M Brett; Travis R Taylor; Elaine J Carlson; Thomas E Ferrin; Esteban G Burchard; Seymour Packman; Kathleen M Giacomini
Journal:  Mol Pharmacol       Date:  2006-08-24       Impact factor: 4.436

8.  Mechanism of the regulation of organic cation/carnitine transporter 1 (SLC22A4) by rheumatoid arthritis-associated transcriptional factor RUNX1 and inflammatory cytokines.

Authors:  Tomoji Maeda; Masamichi Hirayama; Daisuke Kobayashi; Keiji Miyazawa; Ikumi Tamai
Journal:  Drug Metab Dispos       Date:  2006-12-01       Impact factor: 3.922

9.  Uptake of cardiovascular drugs into the human heart: expression, regulation, and function of the carnitine transporter OCTN2 (SLC22A5).

Authors:  Markus Grube; Henriette E U Meyer zu Schwabedissen; Damaris Präger; Jeanette Haney; Klaus-Uwe Möritz; Konrad Meissner; Dieter Rosskopf; Lothar Eckel; Michael Böhm; Gabriele Jedlitschky; Heyo K Kroemer
Journal:  Circulation       Date:  2006-02-20       Impact factor: 29.690

10.  Plasma carnitine ester profiles in Crohn's disease patients characterized for SLC22A4 C1672T and SLC22A5 G-207C genotypes.

Authors:  Judit Bene; Katalin Komlósi; Lili Magyari; Gábor Talián; Krisztina Horváth; Beáta Gasztonyi; Pál Miheller; Mária Figler; Gyula Mózsik; Zsolt Tulassay; Béla Melegh
Journal:  Br J Nutr       Date:  2007-03-29       Impact factor: 3.718

View more
  17 in total

1.  Contribution of the IBD5 locus to inflammatory bowel disease: a meta-analysis.

Authors:  Jian Wang; Xi Wang; Hong Yang; Dong Wu; Li Wang; Jiaming Qian
Journal:  Hum Genet       Date:  2011-01-30       Impact factor: 4.132

2.  Pharmacogenomics of membrane transporters: past, present and future.

Authors:  Sook Wah Yee; Ligong Chen; Kathleen M Giacomini
Journal:  Pharmacogenomics       Date:  2010-04       Impact factor: 2.533

Review 3.  Pharmacogenomic discovery using cell-based models.

Authors:  Marleen Welsh; Lara Mangravite; Marisa Wong Medina; Kelan Tantisira; Wei Zhang; R Stephanie Huang; Howard McLeod; M Eileen Dolan
Journal:  Pharmacol Rev       Date:  2009-12       Impact factor: 25.468

4.  ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia.

Authors:  M Li; E L Seiser; R M Baldwin; J Ramirez; M J Ratain; F Innocenti; D L Kroetz
Journal:  Pharmacogenomics J       Date:  2016-11-15       Impact factor: 3.550

5.  Functional characterization of liver enhancers that regulate drug-associated transporters.

Authors:  M J Kim; P Skewes-Cox; H Fukushima; S Hesselson; S W Yee; L B Ramsey; L Nguyen; J L Eshragh; R A Castro; C C Wen; D Stryke; S J Johns; T E Ferrin; P-Y Kwok; M V Relling; K M Giacomini; D L Kroetz; N Ahituv
Journal:  Clin Pharmacol Ther       Date:  2011-03-02       Impact factor: 6.875

Review 6.  The pharmacogenomics of membrane transporters project: research at the interface of genomics and transporter pharmacology.

Authors:  D L Kroetz; S W Yee; K M Giacomini
Journal:  Clin Pharmacol Ther       Date:  2009-11-25       Impact factor: 6.875

7.  Institutional Profile: The University of California Pharmacogenomics Center: at the interface of genomics, biological mechanisms and drug therapy.

Authors:  Deanna L Kroetz; Nadav Ahituv; Esteban G Burchard; Su Guo; Andrej Sali; Kathleen M Giacomini
Journal:  Pharmacogenomics       Date:  2009-10       Impact factor: 2.533

8.  Reduced renal clearance of cefotaxime in asians with a low-frequency polymorphism of OAT3 (SLC22A8).

Authors:  Sook Wah Yee; Anh Nguyet Nguyen; Chaline Brown; Radojka M Savic; Youcai Zhang; Richard A Castro; Cheryl D Cropp; Ji Ha Choi; Diment Singh; Harunobu Tahara; Sophie L Stocker; Yong Huang; Claire M Brett; Kathleen M Giacomini
Journal:  J Pharm Sci       Date:  2013-05-06       Impact factor: 3.534

9.  Using l-Carnitine as a Pharmacologic Probe of the Interpatient and Metabolic Variability of Sepsis.

Authors:  Theodore S Jennaro; Michael A Puskarich; Marc R McCann; Christopher E Gillies; Manjunath P Pai; Alla Karnovsky; Charles R Evans; Alan E Jones; Kathleen A Stringer
Journal:  Pharmacotherapy       Date:  2020-08-10       Impact factor: 4.705

10.  Genetic variation in the proximal promoter of ABC and SLC superfamilies: liver and kidney specific expression and promoter activity predict variation.

Authors:  Stephanie E Hesselson; Pär Matsson; James E Shima; Hisayo Fukushima; Sook Wah Yee; Yuya Kobayashi; Jason M Gow; Connie Ha; Benjamin Ma; Annie Poon; Susan J Johns; Doug Stryke; Richard A Castro; Harunobu Tahara; Ji Ha Choi; Ligong Chen; Nicolas Picard; Elin Sjödin; Maarke J E Roelofs; Thomas E Ferrin; Richard Myers; Deanna L Kroetz; Pui-Yan Kwok; Kathleen M Giacomini
Journal:  PLoS One       Date:  2009-09-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.